National Eye

Old Dominion University, HaptX, and Georgia Tech Win Grant Award for Project to Advance VR for Vision-Impaired

Retrieved on: 
Tuesday, April 23, 2024
Transfer, Education, National Eye, Paratriathlon, Bangladesh Technical Education Board, System, UI, World Health Organization, Electricity, Doctor of Philosophy, Research, Experiential learning, National Eye Institute, Associate professor, Visual impairment, Employment, VR, Google Images, Computer, National Institutes of Health, Georgia Tech, ODU, Obstetrics, Perception, Old Dominion University, Quality of life, Algorithm

REDMOND, Wash., April 23, 2024 /PRNewswire/ -- To investigate the use of advanced touch simulation for improving accessibility to digital information, the U.S. Department of Health and Human Services, National Institutes of Health, and National Eye Institute have awarded a Phase 1 Small Business Technology Transfer program grant to a research team from Old Dominion University (ODU), HaptX, and Georgia Institute of Technology to investigate "Glove-based Tactile Streaming of Braille Characters and Digital Images for the Visually Impaired." 

Key Points: 
  • "By unlocking access to the vast array of content previously inaccessible to people with limited sight, this project intends to make digital inclusivity a tangible reality."
  • Dr. Bruce Walker currently leads a project using HaptX Gloves for submarine safety training at Georgia Tech's Sonification Lab.
  • This new collaboration between HaptX, ODU, and Georgia Tech will bring dynamic Braille and much more to blind and low-vision users.
  • By bridging the accessibility gap for the visually impaired, the ODU-HaptX-Georgia Tech project opens new realms of engagement with spatial computing environments.

Eye Care Organizations Unite to Save Sight of Premature Infants Using Artificial Intelligence

Retrieved on: 
Thursday, September 21, 2023
Retina, Telehealth, Partnership, National Eye, Life, DL, Oregon Health & Science University, Oxygen, Ophthalmology, Research, Paratriathlon, Eye, Patient, Premature, Orbis International, Risk, Child, SUNY Downstate Health Sciences University, ROP, Artificial intelligence, Diagnosis, National Eye Institute, FDA, National Institute for Health and Care Excellence, Disease, Pharmaceutical industry, Nursing, Birth control, Medical device, Orbis, AI

NEW YORK, Sept. 21, 2023 /PRNewswire/ -- Eye care nonprofit Orbis International is excited to announce a new strategic partnership with Siloam Vision to use the company's cloud-based telemedicine platform to expand access to eye care and prevent blindness in premature infants living in hard-to-reach communities. Siloam Vision's artificial intelligence (AI) platform helps diagnose retinopathy of prematurity (ROP) – the leading cause of childhood blindness globally.

Key Points: 
  • Siloam Vision's artificial intelligence (AI) platform helps diagnose retinopathy of prematurity (ROP) – the leading cause of childhood blindness globally.
  • Orbis and Siloam Vision have aligned missions to make sure no child starts out life blind from an avoidable cause.
  • We are excited to partner with Orbis to help save the sight of more preterm babies in hard-to-reach-communities."
  • Orbis is working to ensure eye care professionals everywhere can access these tools for free.

The Worldwide Age-related Macular Degeneration Industry is Expected to Reach $17.9 Billion by 2030 at a 6.9% CAGR - ResearchAndMarkets.com

Retrieved on: 
Friday, December 9, 2022
Pharmaceutical, Health, Optical, U.S. FDA, AMD, Macular degeneration, Royal commission, Patient, Prevalence, Research, Retina, Roche, FDA, Market share, Investment, European Commission, Age, National Eye Institute, Growth, Novartis, PDUFA, National Eye, Segmental analysis (biology), Patent, Faricimab, BLA, Publishing, Pharmaceutical industry, Coal

National Eye Institute statistics suggest that the prevalence of advanced age-related macular degeneration in the U.S. was approximately 3 million in 2020.

Key Points: 
  • National Eye Institute statistics suggest that the prevalence of advanced age-related macular degeneration in the U.S. was approximately 3 million in 2020.
  • There are no approved drugs available yet to treat dry age-related macular degeneration.
  • This creates an opportunity for market players to address the unmet medical needs of dry AMD patients.
  • In February 2020, Novartis AG received approval for its product, Beovu, a macular degeneration drug from the European Commission for the treatment of patients with age-related macular generation.

Digital home monitoring shows unique predictive value in disease progression for AMD patients

Retrieved on: 
Tuesday, October 25, 2022
Physician, Time, Insurance, Risk, Disease, Claysburg-Kimmel School District, OCT, Alarm monitoring center, Diagnosis, Review, Choroidal neovascularization, National Eye, Patient, NOA, HIV disease progression rates, Home, HOME, Thomas Jefferson University, Severe cognitive impairment, Monitoring, Google Images, Analysis, Medicare, Doctor of Philosophy, AI, CNV, Health, PHP, GLOBE, National Eye Institute, FDA, Home Monitoring Aréna, Inc., AMD, Medical device, Pharmaceutical industry, Medical imaging, Ophthalmology, Retina, MD, Eye

These patients were twice as likely than other dry AMD patients to convert over the same period.

Key Points: 
  • These patients were twice as likely than other dry AMD patients to convert over the same period.
  • The predictive nature of alerts from the AI-enabled ForeseeHome can be invaluable for studying prophylactic treatments for AMD patients.
  • The Notal Vision Monitoring Center is the only ophthalmic digital health provider offering remote monitoring for qualified AMD patients.
  • The ForeseeHome AMD Monitoring Program is a comprehensive program, which includes an FDA-cleared device that monitors visual changes in intermediate dry AMD patients at risk of vision loss from undiagnosed wet AMD.

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Retrieved on: 
Tuesday, August 30, 2022
COVID-19, Human, CEO, Safety, Research, U.S. Securities and Exchange Commission, CATT, GLOBE, Patient, Visual impairment, Inflammation, BLA, KDR, Retina, BRVO, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, VEGF, Food, Nasdaq, FDA, National Eye Institute, Terminology, Syringe, Security (finance), Therapy, Mab, Risk, Ranibizumab, Endothelium, AMD, Review, Marketing, Bevacizumab, Effectiveness, Physician, DME, Diosynth, Retinal, Biologics license application, National Eye, Clinical trial, Annual report, PIER, Pharmaceutical industry, Outlook, Agency, Ophthalmology

In anticipation of potential FDA marketing approval in 2023, Outlook Therapeutics has continued its commercial launch planning.

Key Points: 
  • In anticipation of potential FDA marketing approval in 2023, Outlook Therapeutics has continued its commercial launch planning.
  • These activities include establishing best-in-class partnerships with FUJIFILM Diosynth Biotechnologies for drug substance, and with drug product manufacturer Ajinomoto Bio-pharma Services for finished drug product.
  • NORSE ONE was a clinical experience trial involving 61 wet AMD participants at nine trial sites in Australia.
  • Outlook Therapeutics has submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010 to treat wet AMD.

Efficacy of Notal Vision Home OCT demonstrated by a series of scientific and clinical work

Retrieved on: 
Wednesday, June 29, 2022
Diagnosis, Artificial intelligence, Patient, Alarm monitoring center, Caregiver, GLOBE, Retina, BMC, OCT, Monitoring, ARVO, Doctor of Philosophy, National Eye Institute, AMD, NOA, FDA, Home, Jennifer Loewenstein, Compliance, BioMed Central, CNV, Disease management, Research, HOME, Choroidal neovascularization, Documentation, CEO, Robert A. Holekamp, Severe cognitive impairment, Association for Research in Vision and Ophthalmology, Technology, Longitudinal, AI, SD, Medicare, National Eye, Inc., Review, Health, Home Monitoring Aréna, Macular degeneration, Knut S. Heier, Association, Risk, Therapy, Physician, American Medical Association, Program, Algorithm, Medical device, Medical imaging, Eye, Ophthalmology, MD

Home monitoring using standard of care OCT technology is expected to optimize treatment regimens for these patients and provide better vision outcomes.

Key Points: 
  • Home monitoring using standard of care OCT technology is expected to optimize treatment regimens for these patients and provide better vision outcomes.
  • The investigational Notal Home OCT device, which received an FDA breakthrough designation, is the leading pipeline technology for monitoring wet AMD treatments.
  • A series of studies using Notal Visions Home OCT have shown that the device is effective in overcoming each of these challenges.
  • Notal Visions Home OCT has the potential to support current and future advances in retinal disease management.

GenSight Biologics Announces Publication of a Study of the Impact of LHON Disease on the Lives of Patients and Relatives in Journal of Neuro-Ophthalmology

Retrieved on: 
Thursday, May 19, 2022
Science, Biotechnology, Research, Pharmaceutical, Optical, Health, Genetics, Clinical Trials, Sequence, Work, Sex linkage, Parenting, Guilt, Literature, Participation, Systematic review, University, Moorfields Eye Hospital, National Eye Institute, Incidence, Natural history, Quality of life, Kawasaki, Marketing, Gray platelet syndrome, Research, Optogenetics, Mitochondrial disease, Severe cognitive impairment, Mitochondrion, Department, DNA, Company, Pain, Retina, Doctor of Philosophy, Partner, Patient, REALITY, Eye, Shoulder, Retinal ganglion cell, MTS, VF-14, Disability, MD, BioMed Central, Optic neuropathy, ISIN, Science, University of Cambridge, Neuro, Life, LHON, Union, National Eye, Leber's hereditary optic neuropathy, Mutation, Kawasaki disease, Diagnosis, Cataract, Pharmaceutical industry, Medical device, Medicine, Medical imaging, Phosphorus, Euronext

The study determined that the impact of LHON extends beyond vision-related activity limitations, while addressing its psychosocial impact.

Key Points: 
  • The study determined that the impact of LHON extends beyond vision-related activity limitations, while addressing its psychosocial impact.
  • Additionally, the study determined that despite residing in different countries, LHON patients and their relatives described similar experiences in the four areas of focus in this study.
  • The objective of this study was to comprehensively explore the impact of LHON on the lives of patients and their relatives at the time of diagnosis and now.
  • The Impact of Leber Hereditary Optic Neuropathy on the Quality of Life of Patients and Their Relatives: A Qualitative Study
    1.

Retrospective study covering 2,000 patients over 10 years using ForeseeHome AMD remote monitoring shows substantially better outcomes for patients

Retrieved on: 
Tuesday, April 26, 2022
Home Monitoring Aréna, NOA, Inc., CEO, OCT, Veni, vidi, vici, Severe cognitive impairment, Population, Digital, MD, Disease management, Hospital Insurance and Diagnostic Services Act, Diagnosis, Alarm monitoring center, Retina, Analysis, Visual acuity, AMD, GLOBE, Doctor of Philosophy, Program, Patient, National Eye Institute, Home, CNV, PHP, Choroidal neovascularization, IRIS, Wet, HOME, National Eye, American Academy, Physician, FDA, Risk, Medicare, Medical device, Health insurance, Medical imaging, Eye

The study showed remarkable long-term visual outcomes for patients participating in the Medicare covered, AI-enabled ForeseeHome AMD Monitoring Program, provided by the Notal Vision Monitoring Center.

Key Points: 
  • The study showed remarkable long-term visual outcomes for patients participating in the Medicare covered, AI-enabled ForeseeHome AMD Monitoring Program, provided by the Notal Vision Monitoring Center.
  • The retrospective study followed 2,123 dry AMD patients, from five retina specialist practices over a 10-year period, with a goal of understanding visual outcomes of patients participating in the digital healthcare program.
  • The ALOFT study was designed to understand if dry AMD patient remote monitoring provides enhanced visual outcomes for this at-risk population through early detection.
  • Adopting a remote monitoring paradigm to augment the customary interval office visit is a game changer for AMD patients.

Outlook Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD

Retrieved on: 
Thursday, March 31, 2022
BLA, Therapy, DME, Retinal, Research, Mab, CATT, PIER, MD, Biologics license application, VEGF, Nasdaq, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, Annual report, Security (finance), KDR, Pharmacy, Marketing, Risk, UCLA School of Dentistry, Bevacizumab, Retina, Hope, U.S. Securities and Exchange Commission, Terminology, Ranibizumab, AMD, Clinical trial, Public health, Endothelium, BRVO, Inflammation, FDA, Patient, Company, Human, Uveitis, Diosynth, Food, National Eye, Safety, National Eye Institute, File association, COVID-19, Physician, David Geffen School of Medicine at UCLA, Effectiveness, Pharmaceutical industry, Outlook, Ophthalmology, Ophthalmology

If approved, LYTENAVA (bevacizumab-vikg) could replace the current practice of using unapproved repackaged IV bevacizumab sourced from compounding pharmacies for the treatment of wet AMD.

Key Points: 
  • If approved, LYTENAVA (bevacizumab-vikg) could replace the current practice of using unapproved repackaged IV bevacizumab sourced from compounding pharmacies for the treatment of wet AMD.
  • NORSE ONE was a clinical experience trial involving 61 wet AMD participants at nine trial sites in Australia.
  • If approved, ONS-5010 can replace the need to use unapproved repackaged IV bevacizumab from compounding pharmacies for the treatment of wet AMD.
  • Outlook Therapeutics has submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010 to treat wet AMD.

Notal Vision Reports Publication of First U.S. Home OCT Study Results

Retrieved on: 
Tuesday, March 8, 2022
Digital, Risk, CNV, Diagnosis, Documentation, Patient, Artificial intelligence, Home Monitoring Aréna, NOA, Severe cognitive impairment, Disease management, OCT, Doctor of Philosophy, Roche, Medicare, Home, FDA, Goal, Genentech, American Medical Association, Disease, Administration, CEO, Retina, HOME, AMD, Caregiver, Choroidal neovascularization, Review, Technology, Ophthalmology, Physician, Classification, Therapy, National Eye Institute, GLOBE, National Eye, Medical imaging, Medical device, Pharmaceutical industry, Hospital, Eye, MD

Investigators from Ophthalmic Consultants of Boston and Pepose Vision Institute in St. Louis report findings comparing patient self-operated Notal Home OCT using proprietary Notal OCT Analyzer (NOATM) artificial intelligence (AI), with the standard of care in-office OCT analyzed by retina specialists.

Key Points: 
  • Investigators from Ophthalmic Consultants of Boston and Pepose Vision Institute in St. Louis report findings comparing patient self-operated Notal Home OCT using proprietary Notal OCT Analyzer (NOATM) artificial intelligence (AI), with the standard of care in-office OCT analyzed by retina specialists.
  • The investigators found over 95% agreement when comparing retinal fluid detection capability, a primary marker for treatment guidance, between Notal Home OCT and in-office OCT.
  • The results are highly significant for management of patients suffering from wet AMD, the leading cause of blindness in the United States.
  • Notal Visions Home OCT has the potential to support current and future advances in retinal disease management.